TWI389686B - 外用醫藥組成物 - Google Patents
外用醫藥組成物 Download PDFInfo
- Publication number
- TWI389686B TWI389686B TW096107973A TW96107973A TWI389686B TW I389686 B TWI389686 B TW I389686B TW 096107973 A TW096107973 A TW 096107973A TW 96107973 A TW96107973 A TW 96107973A TW I389686 B TWI389686 B TW I389686B
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- luliconazole
- present
- external use
- external
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
本發明係關於一種外用醫藥組成物,特別是關於一種外用醫藥組成物,其可於抑制光學純度降低之狀態下儲存。
日本群島延伸於亞熱帶地區至溫帶地區,且具有溫和氣候及高溼度,易有促使例如黴菌之真菌類繁殖的傾向。此外,由於衣著之西化,人們現已習慣於穿著鞋類於腳上。因此,腳提供了真菌類繁殖之良好環境,導致現今社會流行之黴菌性皮膚病。其中,甲黴菌病(onychomycosis)具有低完全治癒率及高復發及再感染率。因此,需要一種有效之治療。在習用上,主要使用托萘酯(tolnaftate)調配劑之治療已被作為處理此類疾病。近年來,主要使用例如聯苯芐唑(bifonazole)及伊曲康唑(itraconazole)之咪唑系抗真菌劑。
關於咪唑系抗真菌劑,商業上可獲得之咪唑系抗真菌劑有例如下述通式(1)所表示者,明確而言,為以下結構式(1)所示之盧立康唑(luliconazole)及以下結構式(2)所示之拉諾康唑(lanoconazole)。亦有稱為“Lulicon”(已登記商標)之商業上可獲得之產品(例如詳見專利文件1及專利文件2)。盧立康唑為一種具有光學活性之咪唑系抗真菌劑,具有寬廣的抗真菌範圍,特別是,顯示對於皮癬黴菌之顯著的抗真菌活性。此外,盧立康唑之特徵亦為其在角質層之維持特性非常高,因此為一種被期待應用於治療甲黴菌病之組成物。然而,類似其他咪唑系抗真菌劑,盧立康唑及拉諾康唑是在其溶解度上有問題之藥劑,因此其製備時需要使用溶劑。另一方面,在一些情況下,盧立康唑之特性可包括當其在因溶解所使用之溶劑的形式、溫度、酸及鹼等嚴苛的環境下以溶解狀態儲存時,會有降低其光學純度之風險。此外,此類光學純度之降低與溶劑有關,換言之,對於含盧立康唑及/或其鹽類之外用醫藥組成物,被期待提供增加其溶解度同時抑制光學純度之降低的方法,即使在嚴苛的環境下。
光學純度之降低為一般現象,其有時根據儲存條件於光學活性化合物中會發生,特別是在高溫之嚴苛條件下。然而,知道並無方法抑制該現象。
下文,在抗真菌藥劑之醫藥技術中,各種研究已導向增加其溶解度(詳見例如專利文件3至5)。然而,溶解抗真菌藥劑在其溶解度上顯示出增加的差異,因此其中任一者的效果並不能直接應用於其他化合物。在溶劑之中,扮演預防光學活性化合物之光學純度降低之角色的溶劑仍未知。
另一方面,關於含盧立康唑及/或其鹽類之醫藥製劑,已知有一種含薄膜形成劑及聚氧丙烯/聚氧乙烯之共聚物的醫藥製劑(詳見例如專利文件6),但一種含N-甲基-2-吡咯啶酮、碳酸丙烯酯或克羅米通者仍完全未知。此外,製造咪唑系化合物之基本方法亦已為技術上所熟知(詳見例如專利文件7):
其中X代表氫原子或氯原子。
專利文件1:JP 10-226686 A專利文件2:JP 2-275877 A專利文件3:JP 5-306223 A專利文件4:JP 7-206711 A專利文件5:WO 96/11710專利文件6:WO 03/105841專利文件7:JP 62-93227 A
本發明在此情況下完成,且本發明之一目的在提供一種溶解盧立康唑及/或其鹽類(以下稱為盧立康唑或其類似物)之技術,並於抑制光學純度降低之情況下儲存盧立康唑或其類似物。
考量此情形,本發明者已完成深入之研究及成果,獲得溶解盧立康唑及/或其鹽類及於抑制光學純度降低之情況下儲存盧立康唑或其類似物之技術,且經由發現除了以溶解盧立康唑或其類似物於例如N-甲基-2-吡咯啶酮、碳酸丙烯酯或克羅米通(crotamiton)之有機溶劑增加盧立康唑或其類似物之溶解度之外,可將盧立康唑或其類似物在抑制其光學純度降低之情況下儲存,而最終完成本發明。換言之,本發明如下所述:(1)一種外用醫藥組成物,包括:i)以下列結構式(1)所代表之盧立康唑及/或其鹽類;及ii)選自N-甲基-2-吡咯啶酮、碳酸丙烯酯及克羅米通之一種或二種或多種。
(2)根據上述第(1)點所述之外用醫藥組成物,其中該外用醫藥組成物提供作為治療或預防甲黴菌病。
根據本發明,可提供一種外用醫藥組成物,其可在溶解盧立康唑或其類似物並於抑制其光學純度降低之情況下儲存。
(1)盧立康唑及/或其鹽類作為外用醫藥組成物之主要成分(下文中稱為本發明之醫藥組成物)本發明之外用醫藥組成物含有作為主要成份之盧立康唑及/或其鹽類。上述盧立康唑以上述結構式(1)為代表,上述盧立康唑為已知化合物,其以(R)-(-)-(E)-[4-(2,4-二氯苯基)-1,3-亞二硫-2-基]-1-咪唑基乙腈((R)-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazol e acetonitrile)為代表,其之製造方法及抗真菌特性為技術上所熟知。JP 62-93227 A(上述專利文件7)可使用作為參考。此外,“其鹽類”並無特別限定,只要其為生理上可接受性。其較佳之實例包括:無機酸鹽,例如氯化氫、硝酸鹽、硫酸鹽及磷酸鹽;有機酸鹽,例如檸檬酸鹽、草酸鹽、乳酸鹽及乙酸鹽;及含硫酸之鹽,例如甲磺酸鹽及甲苯磺酸鹽。就安全性及溶解度而言,以氯化氫更佳。
在本發明之外用醫藥組成物中,盧立康唑或其類似物之含量關於醫藥組成物總量,較佳為0.1至30質量%,更佳為0.5至15質量%。盧立康唑或其類似物之含量可根據其溶解度及調配劑之特性而決定。
(2)本發明之外用醫藥組成物之主要成份:N-甲基-2-吡咯啶酮、碳酸丙烯酯、或克羅米通本發明之外用醫藥組成物含選自N-甲基-2-吡咯啶酮、碳酸丙烯酯及克羅米通之一種或二種或多種作為主要成份。顯然地,關於有機溶劑,其可使用其單一種類或其二種或多種之組合。在本發明之醫藥組成物中,上述有機溶劑之中,較佳地至少含有N-甲基-2-吡咯啶酮,尤其是含N-甲基-2-吡咯啶酮及碳酸丙烯酯二者。此較佳態樣之有機溶劑不僅在溶解盧立康唑或其鹽類之作用上優異,而且在溶解狀態抑制光學純度降低之作用亦為優異。為了充分發揮此作用,此溶劑之總含量關於醫藥組成物總量,較佳為0.1至40質量%,更佳為1至10質量%。
(3)本發明之外用醫藥組成物本發明之外用醫藥組成物除上述之外可含有在醫藥組成物中通常使用之任何成分,只要其並不會減少本發明之效果即可。
此成分較佳實例包括:碳氫化合物類,例如凡士林及微晶蠟;酯類,例如荷荷巴油(jojoba oil)及鯨蠟;三酸甘油酯類,例如牛脂及橄欖油;高級醇類,例如鯨蠟醇及油醇;脂肪酸,例如硬脂酸及油酸;醇類,例如乙醇及異丙醇;多元醇類,例如甘油及1,3-丁二醇;水;非離子性界面活性劑;陰離子界面活性劑;陽離子界面活性劑;兩性界面活性劑;稠化劑類,例如聚乙烯吡咯啶酮及卡波醇(carbopol);防腐劑;UV吸收劑;抗氧化劑;色素;及粉末。這些任意成分及上述成分可以一般製程處理,藉以可製備本發明之外用醫藥組成物。本發明之外用醫藥組成物並不受特別限制,只要其調配成用於外用醫藥組成物之任何形式,且其較佳實例包括洗劑、乳劑、凝膠劑、乳霜藥劑、霧劑、指甲油劑、及凝膠貼片。此等中以洗劑為最佳。為了安定例如盧立康唑溶液之清澈及顏色,最佳含有50至90質量%之乙醇。
本發明之外用醫藥組成物利用盧立康唑或其類似物之特性較佳使用於治療黴菌性疾病或預防疾病之進行。該黴菌性疾病包括:足部髮癬菌症,例如香港腳;錢癬(trichophytosis corporis),例如念珠菌(candida)及花斑癬(pityriasis versicolor);及硬角質部之髮癬菌症、例如甲黴菌病。因為顯著之效果,其特佳地使用本發明之外用醫藥組成物於治療硬角質部,例如甲黴菌病。尤其是,本發明之外用醫藥組成物在指甲上發揮較佳之效果,並在局部皮癬菌症上發揮此效果。因此,施用滿足本發明之組合的外用醫藥組成物對抗皮癬菌症亦包含於本發明之技術範圍內。此皮癬菌症包括髮癬菌症,例如足部髮癬菌症,特別是外角質部增生型角化過度髮癬菌症,其出現於腳後跟等處。在上述皮癬菌症中,本發明在外角質部增生型角化過度髮癬菌症具有顯著較佳之效果,習知藥劑於該處難以發揮其效果。
關於其之使用,例如該醫藥組成物施用於患部一日一或數次,且治療以每日進行較佳。尤其是,對於甲黴菌病,以一般調配劑無法達到之量的盧立康唑或其類似物作為有效成分可轉移至指甲內。因此,可僅經由外部施用即可治療甲黴菌病,而不需長期飲用抗真菌劑。此外,復發及再感染已為甲黴菌病之主要問題,然而,復發及再感染可經由症狀減輕後投與本發明外用醫藥組成物1至2週預防。因此,本發明之外用醫藥組成物在此方面發揮預防之功效。
以下,本發明將參照實施例更詳細描述。然而,本發明並不受這些實施例之限制。
根據表1所示之調配劑,製備各含本發明外用醫藥組成物之醫藥製劑1至6,即,調配劑成分於室溫攪拌,然後將醫藥製劑之成分溶解,因此獲得清澈洗劑劑量型式之醫藥製劑。於此,值代表“質量%”。同樣地,根據表2,亦製備用於各比較實施例之比較性醫藥製劑1至4。
將上述醫藥製劑1至6及比較性醫藥製劑1至4在40℃及60℃之條件下進行二週儲存實驗。緊接於儲存實驗之前及之後,所製造之SE體((S)-(+)異構物;其為盧立康唑之對映異構物)量以HPLC量測並以面積百分比表示,以調查其安定性,結果顯示於表3。結果,可確認任何本發明之外用醫藥組成物在抑制光學純度降低之狀態下儲存。
<HPLC條件>所使用之儀器:LC-97系統(Shimadzu Corporation)管柱:CHIRALPACK AD-H 4.6 mm x 250 mm管柱溫度:40℃流動相:水:乙腈=90:11至60:40(30-分鐘梯度條件)流速:0.8 ml/min偵測:UV(波長300 nm)定量分析:使用絕對工作曲線(absolute working curve)之面積百分比法
根據本發明,提供一種外用醫藥組成物,其可在溶解盧立康唑或其類似物並於抑制其光學純度降低之情況下儲存。
Claims (2)
- 一種外用醫藥組成物,包括:i)以下列結構式(1)所代表之盧立康唑及/或其鹽類;及ii)碳酸丙烯酯及/或克羅米通(crotamiton),
- 如申請專利範圍第1項之外用醫藥組成物,其中該外用醫藥組成物提供作為治療或預防甲黴菌病(onychomycosis)之使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006062079 | 2006-03-08 | ||
JP2006215871 | 2006-08-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200744588A TW200744588A (en) | 2007-12-16 |
TWI389686B true TWI389686B (zh) | 2013-03-21 |
Family
ID=38474687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096107973A TWI389686B (zh) | 2006-03-08 | 2007-03-08 | 外用醫藥組成物 |
Country Status (16)
Country | Link |
---|---|
US (3) | US8349882B2 (zh) |
EP (1) | EP2005958B1 (zh) |
JP (1) | JP5160409B2 (zh) |
KR (1) | KR101343291B1 (zh) |
AU (1) | AU2006339842B2 (zh) |
BR (1) | BRPI0621446C1 (zh) |
CA (1) | CA2645070C (zh) |
ES (1) | ES2421613T3 (zh) |
IL (1) | IL193894A (zh) |
MX (1) | MX2008011435A (zh) |
NZ (1) | NZ571819A (zh) |
PL (1) | PL2005958T3 (zh) |
RU (1) | RU2423128C2 (zh) |
TW (1) | TWI389686B (zh) |
WO (1) | WO2007102242A1 (zh) |
ZA (1) | ZA200808531B (zh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006339841B2 (en) | 2006-03-08 | 2012-08-30 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
AU2006339842B2 (en) | 2006-03-08 | 2012-06-07 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
WO2007102243A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
WO2009031644A1 (ja) * | 2007-09-05 | 2009-03-12 | Pola Pharma Inc. | 抗真菌医薬組成物 |
EP2191827B1 (en) | 2007-09-05 | 2013-10-30 | Pola Pharma Inc. | Antifungal composition |
JP5529539B2 (ja) | 2007-09-05 | 2014-06-25 | 株式会社ポーラファルマ | 医薬組成物 |
EP2745692A1 (en) * | 2009-02-13 | 2014-06-25 | Topica Pharmaceuticals, Inc | anti-fungal formulation containing luliconazole |
US9050271B2 (en) | 2009-04-09 | 2015-06-09 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
WO2010117089A2 (en) * | 2009-04-09 | 2010-10-14 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
EP2470178B1 (en) | 2009-08-25 | 2018-10-17 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
EP2579847A1 (en) * | 2010-06-11 | 2013-04-17 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
JP5980700B2 (ja) * | 2012-03-19 | 2016-08-31 | 株式会社ポーラファルマ | 抗真菌医薬組成物が充填された樹脂容器 |
RU2622644C2 (ru) | 2012-09-14 | 2017-06-19 | Пола Фарма Инк. | Кристаллическое вещество и содержащий его фармацевтический препарат |
CN104619320A (zh) | 2012-09-14 | 2015-05-13 | 宝丽制药股份有限公司 | 含有卢立康唑的药物组合物 |
JP5460797B1 (ja) | 2012-09-14 | 2014-04-02 | 株式会社ポーラファルマ | アミド誘導体及び安定性指標としてのその使用 |
EP2895479A1 (en) * | 2012-09-14 | 2015-07-22 | Pola Pharma Inc. | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
US9068958B1 (en) | 2012-09-14 | 2015-06-30 | Pola Pharma Inc. | Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and pharmaceutical composition prepared by containing the crystal |
JP5662495B2 (ja) * | 2013-02-08 | 2015-01-28 | 株式会社ポーラファルマ | 可溶化剤形の医薬組成物 |
JP5730340B2 (ja) * | 2013-02-08 | 2015-06-10 | 株式会社ポーラファルマ | 貯留型医薬組成物 |
JP6067399B2 (ja) * | 2013-02-08 | 2017-01-25 | 株式会社ポーラファルマ | 医薬組成物 |
JP5589110B1 (ja) | 2013-03-08 | 2014-09-10 | 株式会社ポーラファルマ | 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 |
JP6503626B2 (ja) * | 2013-03-28 | 2019-04-24 | 大正製薬株式会社 | 医薬組成物 |
JP6503627B2 (ja) * | 2013-03-28 | 2019-04-24 | 大正製薬株式会社 | 医薬液体組成物 |
WO2014185542A1 (en) | 2013-05-17 | 2014-11-20 | Pola Pharma Inc. | Pharmaceutical composition for treating vaginitis or pneumonia |
JP5680161B1 (ja) | 2013-09-06 | 2015-03-04 | 株式会社ポーラファルマ | 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 |
JP5587488B1 (ja) | 2013-12-12 | 2014-09-10 | 株式会社ポーラファルマ | ルリコナゾールを含有する製剤の評価方法及び指標物質 |
US9480746B2 (en) | 2014-04-21 | 2016-11-01 | Pola Pharma Inc. | Resin container filled with antifungal pharmaceutical composition |
JP6110839B2 (ja) * | 2014-12-04 | 2017-04-05 | 株式会社ポーラファルマ | 可溶化剤形の医薬組成物 |
TR201714882A2 (tr) | 2017-10-03 | 2019-04-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari |
US10898470B1 (en) | 2019-08-13 | 2021-01-26 | Sato Pharmaceutical Co., Ltd. | Pharmaceutical composition containing antifungal agent as active ingredient |
CN112773762B (zh) * | 2019-11-08 | 2023-04-18 | 威智医药股份有限公司 | 外用药物组合物及其制备方法和应用 |
RU2738595C1 (ru) * | 2020-03-17 | 2020-12-14 | Марина Михайловна Бурмина | Лечебно-косметическая композиция |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267169A (en) | 1978-07-22 | 1981-05-12 | Toko Yakuhin Kogyo Kabushiki Kaisha | Novel preparation of clotrimazole |
JPS5815909A (ja) | 1981-07-22 | 1983-01-29 | Toko Yakuhin Kogyo Kk | 抗真菌外用剤 |
US4636520A (en) | 1984-07-16 | 1987-01-13 | Fujisawa Pharmaceutical Co., Ltd. | Antifungal composition employing pyrrolnitrin in combination with an imidazole compound |
JPH0236572B2 (ja) | 1984-11-13 | 1990-08-17 | Hokuriku Pharmaceutical | Suteroidoo177monoesuteruganjukuriimuzai |
JPS6293227A (ja) | 1985-10-19 | 1987-04-28 | Nippon Nohyaku Co Ltd | 抗真菌剤 |
US4764381A (en) | 1985-12-06 | 1988-08-16 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol |
JPH0774144B2 (ja) | 1986-03-12 | 1995-08-09 | 久光製薬株式会社 | 尿素を含有する皮膚用組成物 |
US5686489A (en) | 1986-12-23 | 1997-11-11 | Tristrata Technology, Inc. | Alpha hydroxyacid esters for skin aging |
JPH01246219A (ja) | 1988-03-25 | 1989-10-02 | Nippon Nohyaku Co Ltd | 抗真菌外用クリーム組成物 |
JPH01242525A (ja) | 1988-03-25 | 1989-09-27 | Nippon Nohyaku Co Ltd | 抗真菌外用剤 |
JP3030780B2 (ja) | 1988-12-29 | 2000-04-10 | 日本農薬株式会社 | 光学活性なケテンジチオアセタール誘導体及びその製造方法 |
JPH02264723A (ja) | 1989-04-06 | 1990-10-29 | Taisho Pharmaceut Co Ltd | 抗真菌剤 |
NZ233827A (en) * | 1989-05-26 | 1991-06-25 | Abbott Lab | Pharmaceutical composition comprising clarithromycin, triglyceride oil and stabilising agent |
IL97012A0 (en) | 1990-01-30 | 1992-03-29 | Gist Brocades Nv | Topical preparations for treating human nails |
US5340836A (en) | 1991-02-19 | 1994-08-23 | Mark S. Reinhard | Composition and method for treatment of vaginal yeast infections |
FR2673537B1 (fr) | 1991-03-08 | 1993-06-11 | Oreal | Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes. |
JP2555555B2 (ja) | 1991-07-03 | 1996-11-20 | 武田薬品工業株式会社 | 抗真菌性外用製剤 |
JPH06199701A (ja) | 1992-12-29 | 1994-07-19 | Lion Corp | 外用消炎鎮痛剤 |
JPH06211651A (ja) | 1993-01-12 | 1994-08-02 | Hisamitsu Pharmaceut Co Inc | 爪白癬治療用組成物 |
JPH0774144A (ja) | 1993-06-29 | 1995-03-17 | Sony Corp | プラズマ装置のクリーニング方法 |
RU2134101C1 (ru) | 1993-07-01 | 1999-08-10 | Яманаухи Эуропе Б.В. | Стабильные местнодействующие ретиноидные композиции |
DE4337945A1 (de) * | 1993-11-06 | 1995-05-11 | Labtec Gmbh | Pflaster zur Behandlung von Nagelmykosen |
JP2860748B2 (ja) * | 1993-12-24 | 1999-02-24 | エスエス製薬株式会社 | 安定な酪酸ヒドロコルチゾン含有クリーム剤 |
JP3803393B2 (ja) | 1994-01-12 | 2006-08-02 | 久光製薬株式会社 | 爪白癬治療用組成物 |
JP3629283B2 (ja) | 1994-02-15 | 2005-03-16 | ポーラ化成工業株式会社 | 皮膚外用剤 |
JP3081766B2 (ja) | 1994-05-06 | 2000-08-28 | 東興薬品工業株式会社 | 角質貯留型抗真菌外用組成物 |
GB9420355D0 (en) | 1994-10-10 | 1994-11-23 | Univ Nottingham | Preparation of protein microspheres, films and coatings |
WO1996011710A1 (fr) | 1994-10-13 | 1996-04-25 | Hisamitsu Pharmaceutical Co., Inc. | Preparation externe pour onychomycose |
SE9502244D0 (sv) | 1995-06-20 | 1995-06-20 | Bioglan Ab | A composition and a process for the preparation thereof |
ES2137888B1 (es) | 1995-07-08 | 2001-01-01 | Nihon Nohyaku Co Ltd | Agente antifungico, compuesto para el mismo procedimiento para su produccion y metodo para su utilizacion. |
US6008256A (en) | 1995-08-28 | 1999-12-28 | Showa Yakuhin Kako Co., Ltd. | Composition for local anesthesia |
US5993787A (en) | 1996-09-13 | 1999-11-30 | Johnson & Johnson Consumer Products, Inc. | Composition base for topical therapeutic and cosmetic preparations |
JP4253047B2 (ja) | 1996-09-27 | 2009-04-08 | 杏林製薬株式会社 | 被膜形成性抗真菌剤組成物 |
JP4227677B2 (ja) | 1996-12-10 | 2009-02-18 | 杏林製薬株式会社 | 被膜形成性抗真菌剤組成物 |
JPH10226686A (ja) | 1996-12-10 | 1998-08-25 | Nippon Nohyaku Co Ltd | 光学活性体である(r)−(e)−(4−置換フェニル−1,3−ジチオラン−2−イリデン)−1−イミダゾールアセトニトリル誘導体及び抗真菌剤及びそれらの製造方法 |
AU7936198A (en) | 1998-07-01 | 2000-01-24 | Lead Chemical Co., Ltd. | Ketotifen preparation for percutaneous absorption |
US5962536A (en) | 1998-07-31 | 1999-10-05 | Komer; Gene | Injectable propofol formulations |
AU5404399A (en) | 1998-09-10 | 2000-04-03 | Ipr-Institute For Pharmaceutical Research Ag | Topical application products |
US20040208906A1 (en) | 1999-07-12 | 2004-10-21 | Daiichi Suntory Pharma Co., Ltd. | Pharmaceutical composition for topical administration |
JP2001064206A (ja) * | 1999-08-30 | 2001-03-13 | Isp Japan Kk | 経皮吸収促進組成物 |
US7074392B1 (en) | 2000-03-27 | 2006-07-11 | Taro Pharmaceutical Industries Limited | Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections |
US6428654B1 (en) | 2000-04-05 | 2002-08-06 | Hercules Incorporated | Fungicidal method |
JP2002114680A (ja) | 2000-07-31 | 2002-04-16 | Nippon Nohyaku Co Ltd | 抗真菌剤 |
JP2002193755A (ja) | 2000-12-28 | 2002-07-10 | Sansho Seiyaku Co Ltd | フケ・カユミ防止頭髪用および洗髪用化粧料 |
JP2002284702A (ja) | 2001-01-19 | 2002-10-03 | Teika Seiyaku Kk | 外用抗真菌製剤 |
KR100423666B1 (ko) | 2001-02-07 | 2004-03-18 | 보령제약 주식회사 | 항진균 외용 제제 |
US6585963B1 (en) | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
US20030017207A1 (en) | 2001-05-01 | 2003-01-23 | Lin Shun Y. | Compositions and methods for treating vulvovaginitis and vaginosis |
JP2002363070A (ja) | 2001-06-06 | 2002-12-18 | Yuutoku Yakuhin Kogyo Kk | 経皮吸収貼付剤 |
KR100640039B1 (ko) | 2001-09-04 | 2006-10-31 | 트롬스도르프 게엠베하 운트 코. 카게 알츠나이미텔 | 세르타코나졸을 포함하며, 손발톱의 기능장애와 질환을치료하기 위한 플라스터 |
JP2003252798A (ja) | 2002-02-28 | 2003-09-10 | Shiseido Co Ltd | 抗菌ゲル製剤 |
US8039452B2 (en) | 2002-06-18 | 2011-10-18 | Pola Pharma Inc. | Antifungal medicinal compositions |
US6846837B2 (en) | 2002-06-21 | 2005-01-25 | Howard I. Maibach | Topical administration of basic antifungal compositions to treat fungal infections of the nails |
JP4387639B2 (ja) | 2002-07-16 | 2009-12-16 | 久光製薬株式会社 | 経皮吸収製剤 |
EP1545619B1 (en) | 2002-09-05 | 2008-01-23 | Galderma S.A. | Solution for ungual application |
KR101108439B1 (ko) | 2002-10-25 | 2012-01-31 | 포믹스 리미티드 | 화장료 및 약제용 거품제 |
JP4540667B2 (ja) | 2003-03-21 | 2010-09-08 | ネクスメツド・ホールデイングス・インコーポレイテツド | 抗真菌性ネイルコート |
JP4931128B2 (ja) | 2003-04-10 | 2012-05-16 | ニューロジェシックス, インコーポレイテッド | Trpv1アゴニストの投与のための方法および組成物 |
US20070099932A1 (en) | 2003-06-25 | 2007-05-03 | Toshihiro Shirouzu | External preparation for athlete's foot treatment |
JP4431369B2 (ja) | 2003-11-21 | 2010-03-10 | 久光製薬株式会社 | 抗真菌エアゾール外用製剤 |
JP4429035B2 (ja) | 2004-02-27 | 2010-03-10 | 久光製薬株式会社 | 角質貯留性を高めた外用クリーム製剤 |
JP3783104B2 (ja) | 2004-03-31 | 2006-06-07 | 小林製薬株式会社 | 抗真菌性外用組成物 |
EP1767218B1 (en) | 2004-06-15 | 2016-08-10 | Hisamitsu Pharmaceutical Co., Inc. | Antiinflammatory and analgesic preparation for external use |
JP4690672B2 (ja) * | 2004-07-20 | 2011-06-01 | 岩城製薬株式会社 | 乳剤性皮膚外用剤 |
JP3800232B2 (ja) | 2004-09-30 | 2006-07-26 | 小林製薬株式会社 | 抗真菌性外用組成物 |
JP2006306734A (ja) | 2005-04-26 | 2006-11-09 | Tsumura & Co | 尿素配合外用剤 |
JP5290582B2 (ja) | 2005-12-28 | 2013-09-18 | 帝國製薬株式会社 | 爪用医薬組成物 |
WO2007102243A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
AU2006339841B2 (en) | 2006-03-08 | 2012-08-30 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
AU2006339842B2 (en) | 2006-03-08 | 2012-06-07 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
WO2008075207A2 (en) | 2006-04-04 | 2008-06-26 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
EP2191827B1 (en) | 2007-09-05 | 2013-10-30 | Pola Pharma Inc. | Antifungal composition |
WO2009031644A1 (ja) | 2007-09-05 | 2009-03-12 | Pola Pharma Inc. | 抗真菌医薬組成物 |
JP5529539B2 (ja) | 2007-09-05 | 2014-06-25 | 株式会社ポーラファルマ | 医薬組成物 |
EP2745692A1 (en) | 2009-02-13 | 2014-06-25 | Topica Pharmaceuticals, Inc | anti-fungal formulation containing luliconazole |
WO2010117089A2 (en) | 2009-04-09 | 2010-10-14 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US9050271B2 (en) | 2009-04-09 | 2015-06-09 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
-
2006
- 2006-10-02 AU AU2006339842A patent/AU2006339842B2/en active Active
- 2006-10-02 CA CA2645070A patent/CA2645070C/en active Active
- 2006-10-02 PL PL06811056T patent/PL2005958T3/pl unknown
- 2006-10-02 ES ES06811056T patent/ES2421613T3/es active Active
- 2006-10-02 US US12/281,967 patent/US8349882B2/en active Active
- 2006-10-02 MX MX2008011435A patent/MX2008011435A/es active IP Right Grant
- 2006-10-02 JP JP2008503739A patent/JP5160409B2/ja active Active
- 2006-10-02 BR BRPI0621446A patent/BRPI0621446C1/pt active IP Right Grant
- 2006-10-02 EP EP06811056.8A patent/EP2005958B1/en active Active
- 2006-10-02 RU RU2008139905/15A patent/RU2423128C2/ru active
- 2006-10-02 NZ NZ571819A patent/NZ571819A/en unknown
- 2006-10-02 WO PCT/JP2006/319708 patent/WO2007102242A1/ja active Application Filing
-
2007
- 2007-03-08 TW TW096107973A patent/TWI389686B/zh active
-
2008
- 2008-09-04 IL IL193894A patent/IL193894A/en active IP Right Grant
- 2008-10-07 KR KR1020087024539A patent/KR101343291B1/ko active IP Right Grant
- 2008-10-07 ZA ZA2008/08531A patent/ZA200808531B/en unknown
-
2012
- 2012-12-04 US US13/693,987 patent/US20130096187A1/en not_active Abandoned
-
2016
- 2016-11-03 US US15/342,525 patent/US20170071911A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2008011435A (es) | 2009-02-03 |
WO2007102242A1 (ja) | 2007-09-13 |
RU2008139905A (ru) | 2010-04-20 |
IL193894A (en) | 2015-03-31 |
US20170071911A1 (en) | 2017-03-16 |
IL193894A0 (en) | 2009-09-22 |
BRPI0621446B8 (pt) | 2021-02-02 |
TW200744588A (en) | 2007-12-16 |
US8349882B2 (en) | 2013-01-08 |
EP2005958A4 (en) | 2010-09-15 |
RU2423128C2 (ru) | 2011-07-10 |
PL2005958T3 (pl) | 2013-11-29 |
AU2006339842B2 (en) | 2012-06-07 |
US20090137651A1 (en) | 2009-05-28 |
AU2006339842A1 (en) | 2007-09-13 |
BRPI0621446C1 (pt) | 2021-05-25 |
KR101343291B1 (ko) | 2013-12-18 |
ZA200808531B (en) | 2009-12-30 |
ES2421613T3 (es) | 2013-09-04 |
JPWO2007102242A1 (ja) | 2009-07-23 |
EP2005958B1 (en) | 2013-04-17 |
US20130096187A1 (en) | 2013-04-18 |
BRPI0621446A2 (pt) | 2011-12-13 |
CA2645070C (en) | 2014-02-04 |
NZ571819A (en) | 2011-04-29 |
KR20080111044A (ko) | 2008-12-22 |
BRPI0621446B1 (pt) | 2020-10-13 |
EP2005958A1 (en) | 2008-12-24 |
CA2645070A1 (en) | 2007-09-13 |
JP5160409B2 (ja) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI389686B (zh) | 外用醫藥組成物 | |
US8058303B2 (en) | Pharmaceutical composition for external use | |
US8268876B2 (en) | Pharmaceutical composition for external use | |
CN102387785B (zh) | 抗真菌药物组合物 | |
KR101754697B1 (ko) | 항진균성 약제학적 조성물 | |
WO2014042043A1 (en) | Pharmaceutical composition containing luliconazole | |
MX2014003563A (es) | Agente anti-fungico. | |
RU2457831C1 (ru) | Противогрибковый гель для местного нанесения |